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Huntingtin Acts in the Nucleus to Induce
Apoptosis but Death Does Not Correlate
with the Formation of Intranuclear Inclusions
of the neighboring neurons remain unaffected (Grave-
land et al., 1985; Reiner et al., 1988; Hedreen and
Folstein, 1995; Sapp et al., 1995).
Over a decade ago, linkage analysis of families with
HD led to the identification of the gene IT-15, whose
FreÂ deÂ ric Saudou,*²‖ Steven Finkbeiner,*²‖
Didier Devys,³ and Michael E. Greenberg*²§
*Division of Neuroscience
Department of Neurology
Children's Hospital
mutation causes HD (Group THDCR, 1993). The wild-Boston, Massachusetts 02115
type gene encodes a 350 kDa protein, huntingtin, that²Department of Neurobiology
bears no homology to known proteins. The huntingtinHarvard Medical School
gene contains a polymorphic stretch of repeated CAGBoston, Massachusetts 02115
trinucleotides that encodes a polyglutamine (polyGln)³ Institut de GeÂ neÂ tique et de Biologie
tract within huntingtin. When the number of repeats ex-MoleÂ culaire et Cellulaire (IGBMC)
ceeds 35, the gene encodes a version of huntingtin thatCNRS, INSERM, ULP
leads to disease (Gusella et al., 1996).67404 Illkirch-Strasbourg
It has been hypothesized that the expansion of theFrance
polyGln tract within huntingtin creates a protein epitope
that is distinct from epitopes found in the wild-type hun-
tingtin protein (Trottier et al., 1995a). The new epitope
has been theorized to change the interactions betweenSummary
huntingtin and other proteins, thereby leading to neuro-
degeneration. If polyGln expansions cause neurodegen-The mechanisms by which mutant huntingtin induces
eration by rendering huntingtin toxic, it might be ex-neurodegeneration were investigated using a cellular
pected that all cells that express huntingtin would die.model that recapitulates features of neurodegenera-
However, the huntingtin protein is expressed widelytion seen in Huntington's disease. When transfected
throughout the central nervous system as well as ininto cultured striatal neurons, mutant huntingtin in-
nonneuronal cells, yet only a small subset of these cellsduces neurodegeneration by an apoptotic mechanism.
die in HD (Gutekunst et al., 1995; Sharp et al., 1995;Antiapoptotic compounds or neurotrophic factors
Trottier et al., 1995b).protected neurons against mutant huntingtin. Block-
As a first step toward understanding huntingtin'sing nuclear localization of mutant huntingtin sup-
mechanism of action and the basis for its neuronal sub-pressed its ability to form intranuclear inclusions and
type specificity, recent efforts have been aimed at defin-to induce neurodegeneration. However, the presence
ing the subcellular site of huntingtin action. In recentof inclusions did not correlate with huntingtin-induced
studies, huntingtin has been found within nuclei, peri-death. The exposure of mutant huntingtin-transfected
karya, neurites, and synapses (DiFiglia et al., 1995;striatal neurons to conditions that suppress the forma-
Gutekunst et al., 1995; Sharp et al., 1995; Trottier et al.,tion of inclusions resulted in an increase in mutant hun-
1995b; De Rooij et al., 1996; Saudou et al., 1996). Studiestingtin-induced death. These findings suggest that
of a transgenic mouse model of HD and of the brainsmutant huntingtin acts within the nucleus to induce
of HD patients have shown that mutant huntingtin canneurodegeneration. However, intranuclear inclusions
form aggregates within nuclei known as neuronal intra-may reflect a cellular mechanism to protect against
nuclear inclusions, suggesting that mutant huntingtinhuntingtin-induced cell death.
might induce neurodegeneration by acting in the nu-
cleus (Davies et al., 1997; DiFiglia et al., 1997; Becher
Introduction et al., 1998). The presence of intranuclear inclusions
is specific to mutant huntingtin, and inclusions form
Huntington's disease (HD) is a devastating inherited before neurological symptoms and neurodegeneration
neurodegenerative disease characterized by chorea, occur, suggesting that the aggregation of huntingtin into
personality changes, dementia, and early death (Martin intranuclear inclusions is a required step in neurodegen-
and Gusella, 1986). The characteristic symptoms of pa- eration (Ross, 1997; Davies et al., 1998). However, it has
tients with HD result from the selective death and dys- never been shown directly that huntingtin aggregation
function of specific neuronal subpopulations within the is toxic; it remains possible that huntingtin aggregation
central nervous system. HD leads to significant neuronal is unrelated to the central mechanisms of neurodegener-
ation or that neurons promote the aggregation of mutantdeath within the striatum, the subcortical brain structure
huntingtin as a protective response against more toxic,that controls body movements, and to a lesser extent
soluble forms.within the cortex (Vonsattel et al., 1985). The specificity
The huntingtin protein may undergo other modifica-of neuronal death seen in HD is striking; within the stria-
tions in addition to aggregation that could be importanttum, the enkephalin-containing medium spiny neurons
for its toxic effect. For example, the huntingtin proteinof the striatum are particularly vulnerable, whereas many
contains several consensus sites for the cysteine prote-
ase, CPP32 (Goldberg et al., 1996). The observation that
N-terminal huntingtin fragments cause disease in mouse§ To whom correspondence should be addressed.
‖ These authors contributed equally to the work. transgenic models (Mangiarini et al., 1996) has led to
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the hypothesis that abnormal polyGln expansions might huntingtin that contains a stretch of 68 glutamines would
be expected to produce HD with a juvenile onset,render huntingtin toxic by facilitating its proteolysis by
CPP32 from full-length forms into more toxic N-terminal whereas huntingtin with a stretch of 17 glutamines would
not cause disease.fragments.
While a mouse model of HD has contributed signifi- To test whether huntingtin is capable of inducing neu-
rodegeneration in vitro and to determine if the mecha-cantly to the understanding of the mechanisms of hun-
tingtin-induced neurodegeneration (Mangiarini et al., nisms of death depend on the length of the polyGln
stretch, we transfected striatal neurons with wild-type1996; Davies et al., 1997), cell-based studies represent a
complementary approach, which is also likely to provide (480±17) or mutant huntingtin (480±68) and analyzed the
neurons at various time points following transfection.insight into how huntingtin kills neurons. To characterize
the mechanisms of huntingtin-induced neurodegen- To identify cells that were transfected with the huntingtin
constructs, neurons were cotransfected with a markereration, we have developed a cellular model of HD by
introducing huntingtin into cultured striatal neurons by gene, b-galactosidase. To be certain that each neuron
that expressed the marker gene also expressed thetransfection and then assaying the effect of huntingtin
expression on neuronal survival. We find that huntingtin huntingtin construct, transfections were performed with
a high ratio of huntingtin DNA to marker gene DNA (be-is capable of inducing neurodegeneration in a cell-spe-
cific manner that depends on the presence of the mu- tween 3:1 and 6:1). Under these circumstances, over
95% of the neurons transfected by the marker gene alsotated polyGln stretch. Using this in vitro model of hun-
tingtin-induced neurodegeneration, we find that mutant expressed the huntingtin construct (data not shown).
Between 3 and 12 days following transfection, neuronshuntingtin acts within the nucleus to induce neurode-
generation by an apoptotic mechanism. Although mu- were fixed and immunostained for the expression of
huntingtin and b-galactosidase. Nuclear morphologytant huntingtin's site of action is in the nucleus, the
nuclear aggregates of huntingtin are not sufficient to was visualized with the DNA dye Hoechst 33258. Trans-
fected neurons were analyzed by fluorescence micros-trigger neurodegeneration, and surprisingly their forma-
tion is not correlated with huntingtin-induced apoptosis. copy and blindly scored for signs of neurodegeneration.
By this analysis, we found that a subpopulation of neu-Rather, conditions that disrupt the formation of intra-
nuclear inclusions lead to an acceleration of huntingtin- rons transfected with mutant huntingtin showed clear
signs of neurodegeneration as indicated by neurite lossinduced death. These findings suggest that the forma-
tion of intranuclear inclusions may not be a critical step or destruction, chromatin condensation, and nuclear
pyknosis and fragmentation (Figure 1A). We quantifiedin huntingtin-induced neurodegeneration. We propose
that the intranuclear inclusions may instead be part of the number of transfected neurons that exhibited signs
of neurodegeneration and found that neurons transfecteda protective strategy used by the cell to degrade or
inactivate the toxic mutant huntingtin protein. with 480±68 showed double the rate of death compared
to neurons transfected with 480±17 (Figure 1B). This
2-fold effect is reproducible and was observed in moreResults
than 16 independent transfection experiments.
The expression plasmids that encode the mutant andTransgenic Expression of Mutant Huntingtin Kills
Cultured Neurons in a PolyGln Expansion- and wild-type huntingtin are identical except for the length
of their respective polyGln stretches, suggesting that theCell-Specific Fashion
To elucidate the mechanisms of neurodegeneration in difference in the rate of neurodegeneration in transfected
neurons is due specifically to the difference in the lengthHD and to identify factors that might prevent the degen-
erative process, a cellular model was developed that of the polyGln stretch. To determine if the difference in
the ability of the wild-type and mutant huntingtin torecapitulates features of the neurodegenerative process
that occurs in HD. For the cellular model to be useful, induce neurodegeneration is due to differences in the
accumulation of wild-type or mutant huntingtin, wetwo important features of HD need to be recapitulated
in vitro: (1) huntingtin should kill cultured neurons specif- tested whether the amounts of wild-type or mutant hunt-
ingtin are similar within transfected neurons. Huntingtinically when the polyGln stretch is expanded, and (2) the
mutated huntingtin should specifically kill the subsets immunofluorescence within single transfected neurons
was quantified by serial-section confocal laser micros-of neurons that are vulnerable in vivo. We began by
testing the effects of transfecting striatal neurons with copy. We found that wild-type and mutant huntingtin
are present at similar levels in transfected neurons (dataa fragment of huntingtin that corresponds to the first
480 amino acids of the mouse protein that includes the not shown), suggesting that the increase in neurodegen-
eration caused by mutant huntingtin is not due to thepolyGln stretch. This fragment was chosen because it
corresponds to the N-terminal fragment obtained when altered expression of the mutant huntingtin relative to
the wild-type. Taken together, these results suggest thathuntingtin is cleaved by CPP32 (Goldberg et al., 1996)
and because truncated fragments of huntingtin have transfected huntingtin containing the expanded polyGln
stretch induces striatal neurodegeneration by a mecha-been shown to induce cell death effectively in in vitro
models (Cooper et al., 1998; Li and Li, 1998; Martindale nism that specifically involves the action of the ex-
panded polyGln stretch.et al., 1998). The 480±amino acid fragment of huntingtin
was expressed in striatal neurons in two different forms, Although huntingtin induces striatal neurodegenera-
tion by a mechanism that depends on the polyGlna wild-type form that contains a CAG expansion encod-
ing 17 glutamines (480±17) and a mutant form that con- stretch, it remained possible that the mechanism of
polyGln-induced toxicity in cultured neurons is differenttains a stretch of 68 glutamines (480±68). In humans,
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Figure 1. Transfected Huntingtin Induces Degeneration in Cultured Striatal Neurons in a Way that Depends Specifically on the Length of the
PolyGln Stretch
(A) Fluorescence micrographs of immunostained striatal neurons transfected with wild-type (480±17) or mutant (480±68) forms of huntingtin.
Neurons cotransfected by the marker b-galactosidase and huntingtin immunostain green and red, respectively. Signs of neurodegeneration
and death including a pyknotic, sometimes fragmented nucleus (bottom two rows, right most panels, white arrows) and the absence of
neurites can be found in a higher fraction of neurons that express mutant huntingtin compared with neurons that express wild-type huntingtin
(compare bottom two rows to top row). Scale bar 5 20 mm (bottom row, right panel).
(B) Neurons transfected by mutant huntingtin show twice the rate of death compared with neurons transfected by wild-type huntingtin. Nine
days after transfection there is a statistically significant difference in the death induced by mutant huntingtin (480±68) versus wild-type (480±17).
Data are from seven independent experiments (t[19] 5 3.2; **P , 0.01).
than for HD neurons in vivo. To test further whether the huntingtin selectively induced degeneration of the me-
dium spiny, enkephalin-positive subpopulation of stria-in vitro mechanism of huntingtin-induced neurodegen-
eration closely recapitulated the in vivo mechanism, we tal neurons, the subset of striatal neurons that are partic-
ularly vulnerable in HD (Reiner et al., 1988; Sapp et al.,assessed whether the death induced by transfected
huntingtin occurred specifically in the same neuronal 1995). We found that mutant huntingtin induced signifi-
cantly more death than wild-type huntingtin within en-subpopulations that are vulnerable in HD. This was ac-
complished by investigating whether mutant huntingtin kephalin-positive striatal neurons (Figures 2B and 2C).
By contrast, transfected enkephalin-negative striatalcould also kill cultured neurons from the hippocampus
in vitro, a brain region that is spared in HD (Vonsattel et neurons were resistant to huntingtin toxicity, suggesting
that transfected mutant huntingtin induces neurodegen-al., 1985). Whereas the expression of mutant huntingtin
doubled the level of neurodegeneration in striatal neu- eration in vitro in a highly cell-specific manner that reca-
pitulates the pattern found in HD.rons, in hippocampal neurons we found no increase in
neuronal death when the mutant huntingtin was ex-
pressed (Figure 2A). The fact that striatal but not hippo-
campal neurons are susceptible to the effects of mutant Mutant Huntingtin Induces Neurodegeneration
by an Apoptotic Mechanismhuntingtin suggests that mutant huntingtin induces neu-
rodegeneration in a cell type±specific manner, similar Having developed an in vitro model of HD that exhibits
important features of neurodegeneration of HD in vivo,to that seen in HD in vivo. The failure of mutant huntingtin
to induce neurodegeneration in cultured hippocampal we next investigated the mechanisms by which mutant
huntingtin induces neurodegeneration. By immunocyto-neurons is not due to the decreased expression of mu-
tant huntingtin in hippocampal neurons relative to striat- chemistry, we found evidence of cytopathological fea-
tures of apoptosis in degenerating striatal neuronsal neurons. Quantification of the level of mutant hunting-
tin in hippocampal and striatal neurons revealed that transfected by mutant huntingtin. Nuclei within degener-
ating striatal neurons showed chromatin condensation,in these two types of neurons, the amount of mutant
huntingtin expressed is similar (data not shown). We nuclear pyknosis, or nuclear fragmentation (Figure 1A)
and stained positively by terminal deoxynucleotidylconclude that there are intrinsic differences between
hippocampal and striatal neurons that render striatal transferase-mediated dUTP end labeling (TUNEL) (data
not shown). This is consistent with studies performed onneurons vulnerable to mutant huntingtin and hippocam-
pal neurons resistant. postmortem brains from HD patients that demonstrated
features of apoptosis within degenerating neurons (Dra-To test further the cell-specificity of huntingtin-
induced neurodegeneration in vitro, we asked if mutant gunow et al., 1995; Portera-Cailliau et al., 1995).
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To establish further the role of the apoptotic machin-
ery in huntingtin-induced cell death, we tested whether
we could protect neurons against mutant huntingtin by
blocking known components of the cellular apoptotic
machinery. We found that coexpression with BclXL com-
pletely blocked mutant huntingtin-induced neurodegen-
eration (Figure 3A). We also tested the effects of interfer-
ing with another component of the apoptosis pathway,
the protease/caspase CPP32. The extracellular addition
of the small peptide antagonist of CPP32, Ac-DEVD-
CHO, also completely blocked huntingtin-induced neu-
rodegeneration (Figure 3B). In this experiment, it is likely
that Ac-DEVD-CHO is blocking a late CPP32-dependent
step in the process of huntingtin-induced apoptosis
rather than an earlier step, such as the cleavage of full-
length mutant huntingtin into a smaller toxic form. This
is likely because the Ac-DEVD-CHO inhibition was done
using neurons that express not full-length huntingtin but
rather an N-terminal fragment that corresponds to the
fragment that has been proposed to be generated when
full-length huntingtin is cleaved by CPP32. Taken to-
gether, the microscopic features of cells expressing mu-
tant huntingtin and the protective effects of Ac-DEVD-
CHO and BclXL, suggest that mutant huntingtin induces
degeneration of striatal neurons by an apoptotic mech-
anism.
Trophic Factors Protect Neurons against
Mutant Huntingtin
The fact that extracellular application of the small mole-
cule inhibitor Ac-DEVD-CHO protected neurons against
mutant huntingtin suggested that this cellular model of
HD might be used to identify other neuroprotective fac-
tors that might be useful therapeutically in HD. We tested
the effects on huntingtin-induced apoptosis of two tro-
phic factors: brain-derived neurotrophic factor (BDNF)
and ciliary neurotrophic factor (CNTF). Both CNTF and
BDNF completely protected striatal neurons against
huntingtin-induced apoptosis (Figure 3C) and may prove
efficacious in the treatment of HD. We conclude that theFigure 2. Transfected Huntingtin Induces Neurodegeneration in a
cellular model of huntingtin-induced neurodegenerationCell-Specific Manner
could be used to identify clinically useful neuroprotec-(A) Hippocampal neurons are resistant to huntingtin-induced neuro-
tive agents for HD such as trophic factors or novel, smalldegeneration. Data are from three independent experiments;
ANOVA revealed significant differences for form of huntingtin 3 cell molecules that interfere with survival pathways or the
type (F[1,24] 5 16.88; P , 0.0004). Nine days after transfection there apoptotic machinery.
is a statistically significant increase in the death rate induced by
mutant huntingtin (480±68) compared with wild-type huntingtin (480± Mutant Huntingtin Acts within the Nucleus
17) within striatal neurons (t[14] 5 4.69; P 5 0.0003) but not within
to Induce Neuronal Apoptosishippocampal neurons (t[10] 5 1.1; NS), and the death induced by
To begin to identify the subcellular site where huntingtinmutant huntingtin (480±68) in striatal neurons is significantly different
from all the other cases (Fisher's analysis: ***P , 0.0001). triggers apoptosis, we examined whether mutant hun-
(B) Met-enkephalin-positive but not Met-enkephalin-negative neu- tingtin is present in the nucleus of transfected striatal
rons are susceptible to mutant huntingtin-induced degeneration. neurons. Using an N-terminal fragment of huntingtin
Both Met-enkephalin-negative (solid white arrows) and Met-enkeph- containing the first 171 amino acids of the huntingtin
alin-positive (hollow white arrows) neurons transfected with wild-
coding sequence, we found by immunostaining that thetype huntingtin (480±17) remain healthy (intact nuclei, right panels
of the top two rows). In contrast, Met-enkephalin-positive neurons
transfected by mutant huntingtin (480±68) commonly degenerate
(hollow white arrow, third row from the top) whereas untransfected
Met-enkephalin-positive neurons are generally healthy (hollow white a statistically significant increase in the death rate induced by mu-
arrow, bottom row). Scale bar 5 15 mm (bottom row, right panel). tant huntingtin (480±68) compared with wild-type huntingtin (480±17)
(C) Met-enkephalin-positive (Met-Enk1) but not Met-enkephalin- within Met-enkephalin-positive neurons (t[13] 5 4.47; P 5 0.0006) but
negative (Met-Enk2) neurons are susceptible to mutant huntingtin- not within Met-enkephalin-negative neurons (t[13] 5 0.28; NS), and the
induced degeneration. Data are from four independent experiments; death induced by the 480±68 construct in Met-enkephalin-positive
ANOVA revealed significant differences for form of huntingtin 3 cell neurons is significantly different from all the other cases (Fisher's
type (F[1,26] 5 6.59; P 5 0.016). Nine days after transfection there is analysis: ***P , 0.001).
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Figure 3. Mutant Huntingtin-Induced Apo-
ptosis Is Prevented by Antiapoptotic Com-
pounds and Neurotrophic Factors
(A) BclXL cotransfection blocks huntingtin-
induced neurodegeneration. Wild-type or mu-
tant huntingtin was transfected with an ex-
pression vector encoding the human BclXL
protein or with the corresponding empty vec-
tor (Control, pcDNAI), and the percentage of
death was determined 9 days after transfec-
tion. Data are from three independent ex-
periments; ANOVA revealed significant dif-
ferences for form of huntingtin 3 vector
(F[1,20] 5 7.48; P 5 0.0013). There is a statistically significant increase in the death rate induced by mutant huntingtin compared with wild-type
huntingtin when transfected with empty vector (t[10] 5 2.76; P 5 0.02) but not when transfected with BclXL (t[10] 5 0.59; NS), and the death
induced by the 480±68 construct with the empty vector is significantly different from all the other cases (Fisher's analysis: **P , 0.01).
(B) The extracellular addition of the CPP32 antagonist, Ac-DEVD-CHO, protects neurons against mutant huntingtin. Striatal neurons transfected
with the wild-type or mutant huntingtin were treated with the caspase-3 inhibitor Ac-DEVD-CHO, and the percentage of death was determined
9 days after transfection. Data are from three independent experiments; ANOVA revealed significant differences for form of huntingtin 3
treatment (F[1,19] 5 4.63; P 5 0.044). There is a statistically significant increase in the death rate induced by mutant huntingtin compared with
wild-type huntingtin without treatment (t[9] 5 2.37; P 5 0.042) but not with treatment (t[10] 5 0.12; NS), and the death induced by mutant
huntingtin (480±68) without treatment is significantly different from all the other cases (Fisher's analysis: **P , 0.01).
(C) Brain-derived neurotrophic factor or ciliary neurotrophic factor protects neurons against huntingtin-induced neurodegeneration. Striatal
neurons transfected with the wild-type or mutant huntingtin were treated with different trophic factors and apoptosis was determined 9 days
after transfection. Data are from three independent experiments; ANOVA revealed significant differences for form of huntingtin 3 treatment
(F[2,29] 5 16.75; P , 0.0001). Fisher's analysis revealed a significant increase in the death rate induced by mutant huntingtin compared with
wild-type huntingtin without treatment (P , 0.0001) but not when treated with CNTF (P 5 0.44; NS) or BDNF (P 5 0.10; NS), and the death
induced by mutant huntingtin (480±68) without treatment is significantly different from all the other cases (**P , 0.01).
mutant (171±68-Flag) but not wild-type (171±17-Flag) interfered with intranuclear inclusion formation by di-
rectly modifying the ability of mutant huntingtin to aggre-huntingtin appeared in the nucleus as large ovoid aggre-
gates (Figure 4A). Perinuclear inclusions were rarely ob- gate rather than by preventing the accumulation of mu-
tant huntingtin in the nucleus. To test whether mutantserved (less than 1% of the transfected neurons). These
nuclear aggregates appear similar to the intranuclear huntingtin-NES is capable of aggregating, we tested the
effects of leptomycin B, an inhibitor of nuclear exportinclusions described in HD patients and in HD transgenic
mice (Davies et al., 1997; DiFiglia et al., 1997; Becher et (Nishi et al., 1994; Kudo et al., 1997), on the ability of
mutant huntingtin-NES to form aggregates. We foundal., 1998).
We then tested whether nuclear localization was nec- that the extracellular addition of leptomycin B led to the
formation of intranuclear inclusions within a fraction ofessary for huntingtin-induced neurodegeneration. To
block the nuclear localization of huntingtin, we added neurons transfected by mutant huntingtin-NES (Figure
4C, quantitation not shown). In contrast, intranucleara small nuclear export signal (NES) onto the 171±17-
Flag or 171±68-Flag constructs. If huntingtin acts within inclusions were never seen in neurons transfected with
wild-type huntingtin-NES and treated with leptomycinthe nucleus to trigger apoptosis, then we would predict
that the addition of an NES to huntingtin should block the B (Figure 4C, quantitation not shown) or in untreated
neurons transfected with mutant huntingtin-NES (Figureability of huntingtin to enter the nucleus and to induce
neurodegeneration. If huntingtin acts in the cytoplasm 4A). Thus, the addition of an NES to mutant huntingtin
appears to block its ability to form intranuclear inclu-to induce neuronal degeneration, then the addition of
an NES to huntingtin might block the accumulation of sions by specifically preventing its accumulation within
the nucleus through export of nuclear huntingtin into thehuntingtin within the nucleus but it should increase apo-
ptosis. To test whether the addition of an NES to hun- cytoplasm. Having developed a way to export mutant
huntingtin from the nucleus into the cytoplasm withintingtin succeeded in excluding huntingtin from the nu-
cleus, we analyzed transfected cells to see whether neurons, we tested whether the nuclear export of mutant
huntingtin increased or decreased apoptosis. We foundnuclear inclusion formation was blocked. Whereas mu-
tant huntingtin led to the formation of intranuclear inclu- that when mutant huntingtin is exported from the nu-
cleus, the huntingtin protein completely loses its abilitysions within approximately 30% of striatal neurons at 9
days following transfection, the addition of an NES to to induce striatal neurodegeneration (Figures 4A and
4D). Taken together, these results suggest that mutantmutant huntingtin completely blocked inclusion forma-
tion (Figures 4A and 4B). The expression of mutant hun- huntingtin is transported from its site of synthesis in the
cytoplasm into the nucleus where it acts by unknowntingtin-NES was comparable to the expression of mutant
huntingtin lacking the NES as measured by confocal mechanisms to trigger apoptosis.
microscopy at a time point preceding the formation of
intranuclear inclusions, suggesting that the failure of Intranuclear Inclusions and Huntingtin-Induced
Neurodegenerationmutant huntingtin-NES to form intranuclear inclusions
is not due to poor expression (data not shown). A current hypothesis is that huntingtin accumulation
within the nucleus leads to neurodegeneration throughHowever, it remained possible that the addition of the
short 10±amino acid nuclear export tag to huntingtin the formation of potentially toxic intranuclear inclusions.
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Figure 4. Mutant Huntingtin Forms Intranu-
clear Inclusions and Acts within the Nucleus
to Induce Apoptosis
(A) Mutant huntingtin induces the formation
of intranuclear inclusions, but the addition of
a nuclear export signal completely blocks the
formation of intranuclear inclusions. A series
of fluorescence micrographs are shown of
neurons double stained for the transfection
marker, b-galactosidase (shown in green),
and the flag epitope (shown in red), which
has been added to the wild-type and mutant
forms of huntingtin (171±17 Flag, 171±68
Flag). Neurons transfected with wild-type
huntingtin do not develop intranuclear inclu-
sions (compare middle panels of the first and
second rows from the top of the figure) or
show nuclear signs of apoptosis (first and
second rows, right panels, solid white arrows)
whether or not a nuclear export signal has
been added to huntingtin. By contrast, mu-
tant huntingtin (171±68 Flag) forms large
ovoid, intranuclear aggregates (middle panel,
hollow arrows) that appear to displace chro-
matin, as shown by a reduction in Hoechst
staining within the center of a nucleus (third
row, right panel, solid white arrow), or are
associated with nuclear signs of apoptosis
such as pyknosis (fourth row, right panel,
solid white arrow). If a nuclear export signal is added to mutant huntingtin (NES-171±68 Flag), both intranuclear inclusion formation and
apoptosis are blocked (bottom row, middle and right panels, respectively). Scale bar 5 7 mm (bottom row, right panel).
(B) The addition of a nuclear export signal (NES) completely blocks the formation of intranuclear inclusions within transfected neurons. Wild-
type or mutant huntingtin containing an NES sequence were transfected into striatal neurons and assessed for the presence of nuclear
inclusions 9 days after transfection. Data are from three independent experiments; ANOVA revealed significant differences for the constructs
(F[3,39] 5 213.2; P , 0.0001). The number of inclusions induced by mutant huntingtin (171±68-Flag) is significantly different from all the other
cases (Fisher's analysis: ***P , 0.0001). The bars plotted on the graph that represent 171-17-Flag, NES-171-17-Flag, and NES-171-68 are not
visible because the corresponding values are 0%.
(C) Blockade of the nuclear export of mutant huntingtin-NES (NES-171±68 Flag) by leptomycin B (10 ng/ml, 24 hr) leads to the formation of
ubiquitinated intranuclear inclusions (bottom row, right panel, solid white arrows). For more details about ubiquitination see text and Figure
5A. The inclusions arise specifically from the accumulation of mutant huntingtin as wild-type huntingtin does not form inclusions in the
presence of leptomycin B (top row, right panel). Scale bar 5 5 mm (bottom row, right panel).
(D) The addition of a nuclear export signal inhibits mutant huntingtin-induced apoptosis. Wild-type or mutant huntingtin containing an NES
sequence was transfected into striatal neurons and assessed for apoptosis 9 days after transfection. Data are from three independent
experiments; ANOVA revealed significant differences for the constructs (F[3,39] 5 55.1; P , 0.0001). Death induced by the NES-171±68-Flag is
statistically different from the death induced by 171±68-Flag construct (t[19] 5 9.49; P , 0.0001) but not from the control constructs 171±17-
Flag (t[20] 5 0.78; NS) and NES-171±17-Flag (t[20] 5 0.72; NS), and the death induced by the 171±68-Flag construct is significantly different from
all the other cases (Fisher's analysis: ***P , 0.0001).
It has also been suggested that the formation of intra- vitro model of HD resemble closely those found in vivo
in HD in mice and humans.nuclear inclusions is a parallel process that is unrelated
to the central mechanism that leads to neurodegenera- If ubiquitinated inclusions must form in order for mu-
tant huntingtin to induce neurodegeneration, then thetion. To investigate the role that huntingtin-containing
intranuclear inclusions play in the process of huntingtin- appearance of inclusions should be detected before
significant apoptosis occurs. To compare the develop-induced neurodegeneration, we first tested whether the
intranuclear inclusions that form in transfected striatal ment of ubiquitinated intranuclear inclusions to the in-
duction of apoptosis, we fixed neurons transfected byneurons resemble the intranuclear inclusions that form
in patients with HD or in transgenic mice. One character- mutant huntingtin at various times following transfec-
tion. Immunocytochemical analysis revealed that theistic feature of the huntingtin intranuclear inclusions de-
tected in HD transgenic mice and found in human au- fraction of striatal neurons expressing mutant huntingtin
that exhibits intranuclear inclusions rises to a peak at 6topsy specimens is that huntingtin within the inclusion
is ubiquitinated. By immunocytochemistry using an anti- days and then falls back to basal levels at 9 and 12 days
posttransfection (Figure 5B). By contrast, at 3 and 6ubiquitin antibody, the huntingtin-containing inclusions
that form in cultured striatal neurons transfected with days posttransfection, mutant huntingtin has not yet
induced apoptosis in a significant number of cells. How-mutant huntingtin were also found wholly within the nu-
cleus and were in each case ubiquitinated (Figures 4C ever, at 9 and 12 days posttransfection the difference
in the percentage of transfected neurons undergoingand 5A). Taken together, the observations that only mu-
tated versions of huntingtin form intranuclear inclusions apoptosis grows substantially. Thus, in cultured striatal
neurons, the formation of intranuclear inclusions pre-and that these aggregates are markedly ubiquitinated
show that the intranuclear inclusions that form in the in cedes temporally the appearance of apoptosis.
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We obtained further evidence that the formation of
mutant huntingtin-containing intranuclear inclusions is
not directly correlated with mutant huntingtin-induced
cell death by assessing the formation of intranuclear
inclusions in striatal neurons that had been protected
against mutant huntingtin by cotransfection with BclXL
or by the application of Ac-DEVD-CHO, CNTF, or BDNF.
None of the protective agents blocked the formation of
intranuclear inclusions. Rather, the fraction of mutant
huntingtin-transfected neurons that showed intranu-
clear inclusions was significantly increased when the
neurons also expressed BclXL or were exposed to Ac-
DEVD-CHO, CNTF, or BDNF (Figures 6A and 6B). This
suggests that the formation of intranuclear inclusions
of huntingtin does not irrevocably commit the neuron
to an apoptotic fate. Although neuronal survival was
correlated with an increase in the presence of intra-
nuclear inclusions, this result by itself does not neces-
sarily indicate that intranuclear inclusions are protective.
Another possibility is that the formation of intranuclear
inclusions is sufficient to initiate the apoptotic process
but that BclXL and Ac-DEVD-CHO protect neurons
against the effects of the nuclear inclusions by interfer-
ing with the downstream execution of apoptosis.
To explore the dependence of neurodegeneration
upon the formation of intranuclear inclusions, we char-
acterized the relationship between inclusion forma-
tion and apoptosis. It has been shown previously that
N-terminal fragments of huntingtin form inclusions more
readily than full-length forms (Cooper et al., 1998; Li and
Li, 1998; Martindale et al., 1998). If intranuclear inclu-
sions are required for huntingtin-induced apoptosis in
striatal neurons, then the efficacy with which different-
sized truncated versions of huntingtin induce apoptosis
Figure 5. Intranuclear Inclusions Containing Ubiquitinated Mutant
might be directly correlated with the percentage ofHuntingtin Form before Apoptosis Is Initiated
transfected neurons in which intranuclear inclusions(A) Huntingtin-containing intranuclear inclusions are ubiquitin-posi-
form. To test this idea, we compared the ability of cul-tive. Six days after transfection by mutant huntingtin (480±68),
striatal neurons were fixed and immunostained for huntingtin (red), tured striatal neurons to form intranuclear inclusions
ubiquitin (green), and DNA (blue). Confocal laser microscopic sec- and undergo apoptosis when transfected with full-
tions taken 3 mm apart revealed ovoid aggregates that were immu- length mutant or wild-type huntingtin, with the 480±17
noreactive for both huntingtin (middle row, left panel, solid white
or 480±68 forms of huntingtin, or with the 171±17 orarrow) and ubiquitin (middle row, middle panel, solid white arrow)
171±68 amino acid N-terminal fragments of huntingtin.and were wholly within the nucleus (compare panels within the
We found that, as the length of the N-terminal huntingtinmiddle row to panels within the top and bottom rows). Scale bar 5
10 mm (bottom row, right panel). fragment decreases, the percentage of neurons that
(B) The peak appearance of intranuclear inclusions precedes the contained discernible intranuclear inclusions increased
development of apoptosis.
dramatically both in striatal (Figures 6C and 6E) and
hippocampal neurons (Figure 6C). However, we found
that the percentage of striatal neurons undergoing apo-We found that the formation of intranuclear inclusions
ptosis remained constant when striatal neurons wereis not always associated with huntingtin-induced apo-
transfected with plasmid constructs that direct the ex-ptosis. When hippocampal neurons and striatal neurons
pression of different-sized N-terminal fragments of mu-were transfected with 480±68, or mutant forms of a
tant huntingtin (Figures 6D and 6F). Notably, the numbersmaller 171±amino acid N-terminal fragment of hunting-
of cells undergoing apoptosis did not correlate with thetin (171±68), we found that in both striatal and hippocam-
percentage of neurons that formed intranuclear inclu-pal neurons intranuclear inclusions developed in a sig-
sions (Figures 6C-6F).nificant percentage of the cells (Figure 6C). However,
We considered the possibility that the full-length mu-the 480±68 and 171±68 fragments of huntingtin induced
tant huntingtin might form intranuclear inclusions at aCAG expansion-dependent apoptosis in the striatal neu-
slower rate than the 480±68 and 171±68 proteins. There-rons but not in the hippocampal neurons (Figure 6D).
fore, if we analyzed cells at later times after transfection,This indicates that in certain subsets of neurons, mutant
we might observe an increase in the number of nuclearhuntingtin effectively forms intranuclear inclusions, but
inclusions that are present in full-length mutant hunting-the presence of the inclusions is not sufficient to induce
apoptosis. tin transfected neurons. However, we found that as with
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the 480±68 protein (Figure 5B), after 6 days of transfec-
tion with the full-length mutant huntingtin, the percent-
age of neurons containing intranuclear inclusions is
greater than the percentage of neurons containing nu-
clear inclusions after 9 days of transfection (Figure 6E).
This indicates that the time course with which the full-
length mutant huntingtin forms intranuclear inclusions
is not delayed and raises the possibility that full-length
mutant huntingtin may be capable of inducing apoptosis
without forming discernible intranuclear inclusions.
To examine further the importance of intranuclear in-
clusions for mutant huntingtin-induced cell death, we
analyzed the effect of a dominant interfering mutant of
the ubiquitin-conjugating enzyme hCdc34p(CL→S) on
the ability of mutant huntingtin to induce intranuclear
inclusions formation and neuronal death. A mutant ver-
sion of hCdc34 (hCdc34p[CL→S]) in which Cys-88 and
Leu-97 have been changed into Ser-88 and Ser-97, re-
spectively, has been shown to inhibit the degradation
of the Xenopus cdk inhibitor Xic1 and the ubiquitination
of the mammalian cdk inhibitor p27 (Pagano et al., 1995;
Yew and Kirschner, 1997). Since huntingtin-containing
intranuclear inclusions are ubiquitinated, we reasoned
that we might be able to interfere with the formation of
intranuclear inclusions by blocking the ubiquitination of
mutant huntingtin. This idea was tested by coexpressing
mutant huntingtin and dominant negative hCdc34p(CL→S)
in striatal neurons and then determining if intranuclear
inclusion formation was blocked and, if so, if mutant
huntingtin still induced neurodegeneration in a CAG
Figure 6. Huntingtin-Induced Neural Degeneration Is Not Corre- expansion dependent manner. For this analysis, we
lated with the Formation of Intranuclear Inclusions chose to use truncated fragments of huntingtin con-
(A) Blockade of huntingtin-induced apoptosis by BclXL significantly taining the first 171 amino acids, since the 171±68 con-
increases the percentage of neurons having intranuclear inclusions struct was found to induce intranuclear inclusions in
9 days after transfection (t[6] 5 4.88; **P , 0.01). a high percentage of striatal neurons, thus facilitating(B) Treatment with CNTF, BDNF, and Ac-DEVD-CHO significantly
quantitation of the effect of hCdc34p(CL→S) on intra-increases the percentage of intranuclear inclusions 9 days after
nuclear inclusion formation. Six days after transfectiontransfection (Fisher's analysis: all *P values , 0.05).
(C) The percentage of hippocampal and striatal neurons that exhibit we found that coexpression of hCdc34p(CL→S) with
intranuclear inclusions is inversely related to the length of the mu- 171±68 fragment of huntingtin led to a dramatic de-
tated huntingtin protein. Wild-type and mutant versions of the hun- crease in the number of intranuclear inclusions that were
tingtin corresponding to the N-terminal 480± and 171±amino acid
observed (Figure 7A). hCdc34p(CL→S) had a similar ef-fragments were transfected into striatal and hippocampal neurons,
fect on intranuclear inclusion formation when this domi-and the percentage of intranuclear inclusions was determined 9
nant negative mutant was cotransfected with the 480±68days after transfection. ANOVA revealed significant differences for
form of huntingtin 3 cell type (F[3,18] 5 176.7; P , 0.0001). There was huntingtin construct (data not shown). In these experi-
a significant difference between the 480±68 and 171±68 forms both ments, among the few intranuclear inclusions that we
in striatal neurons (t[9] 5 15.13; P , 0.0001) and hippocampal neurons were able to detect, we never observed an intranuclear
(t[9] 5 16.48; P , 0.0001). For a given mutant huntingtin fragment size, inclusion that was positive for staining with an anti-the percentage of hippocampal neurons that exhibit intranuclear
huntingtin antibody but negative for staining with aninclusions is significantly higher than the percentage of striatal neu-
rons, especially for the 171±68 form of huntingtin (t[4] 5 15.39; P ,
0.0001).
(D) N-terminal fragments of mutant huntingtin induce apoptosis in
striatal but not hippocampal neurons. The percentage of death nuclear inclusions was determined 6 and 9 days after transfection
within striatal and hippocampal neurons was determined 9 days for five independent transfections. The percentage of neurons that
after transfection. Data are from three independent experiments; exhibit intranuclear inclusions is higher at 6 compared to 9 days
ANOVA revealed significant differences for form of huntingtin 3 cell after transfection. No intranuclear inclusions were detected when
type (F[3,55] 5 4.96; P 5 0.0041). There is a statistically significant cells were transfected with full-length wild-type huntingtin (data not
increase in the death rate induced by the 480±68 and 171±68 forms shown).
of huntingtin compared with the 480±17 and 171±17 forms within (F) Full-length mutant huntingtin induces apoptosis in striatal neu-
striatal neurons (t[23] 5 3.46; P 5 0.0021 and t[13] 5 3.07; P 5 0.0089, rons as effectively as more truncated versions of mutant huntingtin.
respectively) but not within hippocampal neurons (t[9] 5 1.26; NS Wild-type and mutant full-length huntingtin were transfected into
and t[10] 5 0.04; NS). The rates of death induced by the 480±68 or striatal neurons, and the percentage of neurons undergoing apopto-
171±68 forms of huntingtin are significantly different from all the sis was determined 9 days after transfection. Data from four inde-
other cases (Fisher's analysis: **P , 0.01). pendent transfections revealed a significant increase in the death
(E) Full-length mutant huntingtin induces the formation of very few rate induced by mutant full-length huntingtin compared to wild-type
intranuclear inclusions in striatal neurons. The percentage of intra- full-length huntingtin (t[17] 5 2.7; *P , 0.05).
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clude that the formation of huntingtin-containing inclu-
sions is not likely to play a positive role in mediating
mutant huntingtin-induced cell death. Instead these ob-
servations suggest that the formation of intranuclear
inclusions may be part of a cellular strategy for degrad-
ing or inactivating toxic forms of huntingtin and, thereby,
protecting the cell from the deleterious effects of mutant
huntingtin.
Figure 7. The Dominant Negative Ubiquitin-Conjugating Enzyme Discussion
hCdc34p(CL→S) Inhibits the Formation of Intranuclear Inclusions
but Accelerates Mutant Huntingtin-Induced Death Process
We have developed a cellular model of Huntington's
(A) Intranuclear inclusion formation induced by mutant huntingtin is
disease that has been useful for elucidating mechanismsdecreased in the presence of hCdc34p(CL→S). Wild-type and mu-
of huntingtin-induced neurodegeneration and for identi-tant forms of huntingtin (171±17, 171±68) were cotransfected with
fying neuroprotective agents that could be used for thean expression vector encoding the human Cdc34(CL→S) mutant
ubiquitin-conjugating enzyme or with the corresponding empty vec- treatment of patients with HD. The expression of hun-
tor (pCS21), and the percentage of neurons that exhibit intranuclear tingtin in cultured striatal neurons causes neurodegen-
inclusions was determined 6 days after transfection. ANOVA re- eration by a mechanism that depends specifically on
vealed significant differences for form of huntingtin 3 vector (F[3,15] 5 the presence of the mutant polyGln stretch and is cell66; P , 0.0001). Fisher's analysis revealed a significant decrease
specific, affecting the same subsets of neurons thatin the percentage of neurons that exhibit intranuclear inclusions
degenerate in HD brains. Using this in vitro model, wewhen mutant huntingtin is transfected with hCdc34p(CL→S) (***P ,
0.0001). Since no inclusions were detected when neurons were show that huntingtin induces neurodegeneration by an
transfected with 171-17 construct, the bars plotted on the graph apoptotic mechanism and that specific inhibitors of apo-
that represent 171-17-empty vector and 171-17 hCdc34p(CL→S) ptosis block huntingtin-induced neurodegeneration. In
are not visible because the corresponding values are 0%.
addition, we have identified two neurotrophic factors,(B) Mutant huntingtin-induced death is increased in the presence of
BDNF and CNTF, that protect transfected neuronshCdc34p(CL→S). Wild-type and mutant forms of huntingtin (171±17,
against huntingtin-induced neuronal death.171±68) were cotransfected with an expression vector encoding the
human Cdc34(CL→S) mutant ubiquitin-conjugating enzyme or with We have begun to elucidate the mechanisms of hun-
the corresponding empty vector (pCS21), and the percentage of tingtin-induced neurodegeneration and have found that
death was determined 6 days after transfection. ANOVA revealed mutant huntingtin translocates to the nucleus to trigger
significant differences for forms of huntingtin 3 vector (F[3,15] 5 13.6; neuronal apoptosis. This finding is in agreement withP , 0.0001). There is a statistically significant increase in the death
studies of transgenic mice expressing mutant ataxin-1rate induced by mutant huntingtin compared to wild-type huntingtin
with a mutated NLS, which demonstrate the critical re-when transfected with hCdc34p(CL→S) (*P , 0.05) but not when
transfected with empty vector (P 5 0.87; NS). quirement of nuclear localization of mutant ataxin-1 for
pathogenesis and aggregate formation in SCA1 (Kle-
ment et al., 1998 [this issue of Cell]). Within the nucleus,
mutant huntingtin forms inclusions, although the per-anti-ubiquitin antibody (data not shown). Taken to-
gether, these results suggest that the decrease in the centage of neurons that display discernible intranuclear
inclusions varies depending on the length of the mutantnumber of intranuclear inclusions that form in the pres-
ence of hCdc34p(CL→S) reflects the fact that under huntingtin fragment that is expressed. Full-length hun-
tingtin forms inclusions very rarely raising the possibilitythese conditions the ubiquitination of mutant huntingtin
is at least partially inhibited and also that the ubiquitina- that the intranuclear inclusions may not play a causal
role in mutant-huntingtin induced death. This finding istion of mutant huntingtin may be a prerequisite for intra-
nuclear inclusion formation. supported by studies of human HD brains in which the
number and the location of inclusions do not correlateHaving identified conditions that lead to the inhibition
of intranuclear inclusion formation, we next investigated with the pattern of neurodegeneration (C.-A. Gutekunst
and S. M. Hersch, personal communication) and by thethe effect of hCdc34p(CL→S) on mutant huntingtin-
induced cell death. In the absence of hCdc34p(CL→S), finding that transgenic mice expressing mutant ataxin-1
in which the self-association domain has been deletedmutant huntingtin induces a significant increase in apo-
ptosis 9 days after transfection while having no detect- develop a pathological phenotype without forming nu-
clear aggregates (Klement et al., 1998). Consistent withable effect at 6 days (Figures 5B and 7B). However,
when transfected with hCdc34p(CL→S), the 171±68 this possibility is our finding that forms of mutant hun-
tingtin (e.g., full-length mutant huntingtin) that rarely ag-fragment of huntingtin caused a significant increase in
cell death relative to the 171±17 huntingtin fragment as gregate to form inclusions trigger striatal neuron apo-
ptosis as effectively as N-terminal fragments of mutantearly as 6 days after transfection (Figure 7B). Similar
results were obtained when the effect of cotransfection huntingtin (e.g., 171±68), which form inclusions quite
frequently. It is possible that differences in the ability ofof hCdc34p(CL→S) with the 480±17 or 480±68 fragments
of huntingtin was assessed (data not shown). Since the full-length mutant huntingtin and the 480±68 and 171±68
huntingtin fragments to form inclusions reflect a differ-presence of hCdc34p(CL→S) in neurons leads to a dra-
matic decrease in the formation of mutant huntingtin ence in the levels of these proteins that accumulate in
striatal neurons with the small fragments accumulatingcontaining intranuclear inclusions, but to an accelera-
tion of CAG expansion dependent cell death, we con- to higher levels and therefore forming inclusions more
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readily. If this proves to be the case it might suggest an excitotoxic model of HD (Emerich et al., 1997), but
whether the effects of CNTF or other agents would provethat lower levels of mutant huntingtin are needed to
induce cell death than for intranuclear inclusion for- useful in blocking huntingtin-induced neurodegenera-
tion was unknown. The demonstration here that CNTFmation.
The possibility that intranuclear inclusion formation and BDNF effectively protect neurons against hunting-
tin-induced death suggests that trophic factor treat-may not be an important step in the mutant huntingtin-
induced death process is corroborated by our finding ments might be a successful strategy for treating HD.
Moreover, understanding the signaling mechanisms bythat hCdc34p(CL→S), a dominant interfering form of an
ubiquitin-conjugating enzyme, dramatically suppresses which CNTF and BDNF suppress huntingtin-induced
apoptosis could provide additional ways of inhibitingthe formation of intranuclear inclusions while accelerat-
ing huntingtin-induced death in a CAG expansion de- the deleterious effect of the mutant huntingtin protein.
Finally, the NES experiments suggest a completely dif-pendent manner. Although it is difficult from our analysis
to identify the direct site of action of hCdc34p(CL→S), ferent strategy for protecting neurons against mutant
huntingtin. If specific molecules within the nuclear enve-we can conclude that intranuclear inclusion formation
can be dissociated from mutant huntingtin-induced cell lope translocate mutant huntingtin from the cytoplasm
into the nucleus, then the selective inhibition of mutantdeath. Taken together, these findings suggest that hun-
tingtin-containing intranuclear inclusions may form as huntingtin import might protect neurons against the sub-
sequent neurodegeneration.the cell attempts to degrade or inactivate the toxic mu-
tant huntingtin protein. As such, the formation of intra-
nuclear inclusions during mutant huntingtin-induced Experimental Procedures
neurodegeneration may represent a cellular survival
Plasmidsstrategy in the face of a serious toxic insult.
The wild-type and mutant full-length huntingtin expression vectorsIf nuclear inclusions are not necessary for huntingtin-
in pCMV-Neo-Bam (Baker et al., 1990) were generated from SV-40-induced death, how then does huntingtin induce neuro-
HD15 (15 CAGs, 17 Glns) and SV-40-HD73 (73 CAGs, 75 Glns) (Trot-
degeneration? We provide evidence that when hunting- tier et al., 1995b). They encode respectively a 17 and 75 polyGln
tin contains a mutated, expanded polyGln stretch, it tract. The expression vectors for the 480±17, 480±68, 171±17 and
171±68 forms of huntingtin correspond to the first 480 or 171 aminotranslocates from its site of synthesis in the cytoplasm
acids of full-length wild-type (HU5A, 17 Glns) or mutant (HU5B, 68into the nucleus where mutant huntingtin accumulates
Glns) huntingtin in pTL1 that were cloned into pcDNAI (Invitrogen).and induces neurodegeneration. The steps that are nec-
The Flag epitope was added in phase at the C terminus of 171±17essary to translocate mutated huntingtin from the cyto-
or 171±68 constructs, while an NES derived from the heat-stable
plasm into the nucleus are not known. Full-length mutant inhibitor (PKI) of cAMP-dependent protein kinase (Wen et al., 1995)
huntingtin is sufficiently large that it would have to be was added at the N terminus.
actively transported across the nuclear envelope to en-
ter the nucleus. Nuclear import may be mediated by a Cell Culture and Transfection
Primary cultures of striatal and hippocampal neurons were preparednuclear localization sequence (NLS) within huntingtin
from embryonic (E16±18) rats and transfected as previously de-(Bessert et al., 1995). It is possible that nuclear import
scribed (Finkbeiner et al., 1997). Forskolin (10 mM; Sigma) and IBMXoccurs more readily if mutant full-length huntingtin is
(100 mM; Sigma) were added to the cultures every 2 days starting
first proteolysed into smaller fragments (Goldberg et 3 days after transfection. Ac-DEVD-CHO (10 mM; Sigma), BDNF (50
al., 1996). However, this does not explain why mutant ng/ml; Amgen), CNTF (50 ng/ml; Regeneron) were added to the
huntingtin, but not wild-type huntingtin, accumulates in cultures every 2 days starting the day of transfection.
the nucleus since both mutant and wild-type huntingtin
contain the same NLS sequence. Furthermore, it re- Immunocytochemistry
The method of immunocytochemistry has been previously publishedmains to be shown that proteolysis is required for full-
(Finkbeiner et al., 1997). Antibodies used include monoclonal anti-length huntingtin to become toxic and to induce neuro-
b-galactosidase (1:300; Promega), monoclonal anti-huntingtin 4C8degeneration.
(1:500; Trottier et al., 1995b), polyclonal anti-ubiquitin (1:100; DAKO),
The finding that the addition of an NES to huntingtin polyclonal anti-b-galactosidase (1:300; 59-39), monoclonal anti-Flag
blocks neurodegeneration indicates that mutant hun- M2 (1:100; VWR), and polyclonal anti-Methionine-Enkephalin-Arg-
tingtin acts in the nucleus and provides insight into the Phe (1:200; Peninsula Laboratories). The specificity of the staining
with the anti-Met-Enk-Arg-Phe antibody was confirmed by double-mechanisms of huntingtin-induced neurodegeneration.
labeling experiments using a monoclonal anti-Enkephalin antibodyIt is possible that mutant huntingtin exerts its effect in
(1:300; Chemicon). Primary antibody binding was variously detectedthe nucleus through interactions with other proteins or
with Cy-2 (1:300; BDS) or Cy-3 (1:300; Jackson Immunoresearch)
DNA. Nuclear mutant huntingtin could interfere with the secondary antibodies.
DNA binding or activation of transcription factors re-
quired for neuronal survival, or mutant huntingtin could Death Measurement
itself function within the nucleus as a transcription factor After immunostaining, neurons were cytochemically labeled with
(Gerber et al., 1994), selectively transactivating genes the DNA dye Hoechst 33258 (2.5 mg/ml, 5 min), and transfected
neurons were scored as healthy or apoptotic by morphological crite-that directly or indirectly regulate apoptosis.
ria. Neurons were scored as apoptotic only when they had a pyknoticThe development of a cellular model should prove
and/or fragmented nucleus and degenerated or absent neurites.useful for further elucidating mechanisms of huntingtin-
Each graph represents at least three independent experiments per-induced neurodegeneration and for the identification
formed in duplicate in which about 150 neurons were individually
of new protective factors that could be used for the examined. Cell death observed with an empty vector was found to
treatment of patients with HD. Previously, it had been be similar to the observed death when neurons are transfected with
the various wild-type versions of huntingtin.shown that CNTF could prevent neurodegeneration in
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